Abstract
Diencephalic syndrome (DS) is a clinical disorder of metabolism associated with poor outcome in children with low-grade gliomas (LGGs). Since survival has been primarily reported with aggressive therapy, we report outcome data for these patients using a current, contrasting chemotherapy-driven approach. We performed a population-based review of DS patients treated with chemotherapy from 1997–2012. Metabolic rate was assessed in selected cases using open-circuit calorimetry to generate resting energy expenditure (REE) data. Tumor tissue was analyzed for BRAF alterations. Survival was compared with an age-related, radiotherapy naïve cohort of non-DS children with location-matched LGGs. Nine children (1.7 % of 520 LGG diagnoses) fulfilled DS criteria. The median diagnostic age was 1.49 years (0.55–2.69 years), although neurofibromatosis Type-I patients were older (p = 0.005). All tumors analyzed exhibited either NF1 mutation or BRAF fusion. Seven tumors were histologically confirmed as low grade astrocytomas, one demonstrated neurocytic features, and one NF1 case was diagnosed using imaging and clinical criteria. All patients received chemotherapy, with seven cases also receiving initial nutritional supplementation. All nine gained weight after only 6 months of treatment. Two DS patients had serial REE measurements, revealing a hypermetabolic state (over 200 % of predicted REE) at diagnosis which reduced to normal range with therapy. First-line chemotherapy treatment resulted in one minor response, stable disease in four cases, with progression in the remaining four patients. Although DS patients demonstrated inferior initial progression-free survival when compared to non-DS counterparts (5 years: 22 versus 60 %, p = 0.015), all DS children remain alive at a median follow up of 5.3 years (1.2–14.9 years) with none requiring radiotherapy. Long-term sequelae included pituitary and visual dysfunction, learning difficulties and paradoxical, inappropriate weight gain. DS can be managed with non-aggressive chemotherapeutic, radiation-sparing strategies supplemented by temporary nutritional support. Multiple lines of therapy may be required to overcome disease progression but excellent survival and metabolic outcomes can be achieved. Continued surveillance is mandatory to prevent significant weight gain and support affected children with clinical sequelae.
Similar content being viewed by others
References
Burr IM, Slonim AE, Danish RK, Gadoth N, Butler IJ (1976) Diencephalic syndrome revisited. J Pediatr 88:439–444
Perilongo G, Carollo C, Salviati L, Murgia A, Pillon M, Basso G, Gardiman M, Laverda A (1997) Diencephalic syndrome and disseminated juvenile pilocytic astrocytomas of the hypothalamic-optic chiasm region. Cancer 80:142–146
Bain HW, Darte JM, Keith WS, Kruyff E (1966) The diencephalic syndrome of early infancy due to silent brain tumor: with special reference to treatment. Pediatrics 38:473–482
Fleischman A, Brue C, Poussaint TY, Kieran M, Pomeroy SL, Goumnerova L, Scott RM, Cohen LE (2005) Diencephalic syndrome: a cause of failure to thrive and a model of partial growth hormone resistance. Pediatrics 115:e742–e748
Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, Warmuth-Metz M, Driever PH, Soerensen N, Kortmann RD, Pietsch T, Faldum A (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol 14:1265–1284
Laithier V, Grill J, Le Deley MC, Ruchoux MM, Couanet D, Doz F, Pichon F, Rubie H, Frappaz D, Vannier JP, Babin-Boilletot A, Sariban E, Chastagner P, Zerah M, Raquin MA, Hartmann O, Kalifa C (2003) Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy—results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 21:4572–4578
Russell A (1951) A diencephalic syndrome of emaciation in infancy and childhood. Arch Dis Child 26:274
Gropman AL, Packer RJ, Nicholson HS, Vezina LG, Jakacki R, Geyer R, Olson JM, Phillips P, Needle M, Broxson EH Jr, Reaman G, Finlay J (1998) Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control. Cancer 83:166–172
Addy DP, Hudson FP (1972) Diencephalic syndrome of infantile emaciation. Analysis of literature and report of further 3 cases. Arch Dis Child 47:338–343
Pimstone BL, Sobel J, Meyer E, Eale D (1970) Secretion of growth hormone in the diencephalic syndrome of childhood. J Pediatr 76:886–889
Brauner R, Trivin C, Zerah M, Souberbielle JC, Doz F, Kalifa C, Sainte-Rose C (2006) Diencephalic syndrome due to hypothalamic tumor: a model of the relationship between weight and puberty onset. J Clin Endocrinol Metab 91:2467–2473
Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17:4790–4798
Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118:1739–1749
Sardi I, Bresci C, Schiavello E, Biassoni V, Fratoni V, Cardellicchio S, Genitori L, Arico M, Massimino M (2012) Successful treatment with a low-dose cisplatin–etoposide regimen for patients with diencephalic syndrome. J Neurooncol 109:375–383
Taveras JM, Mount LA, Wood EH (1956) The value of radiation therapy in the management of glioma of the optic nerves and chiasm. Radiology 66:518–528
Danoff BF, Kramer S, Thompson N (1980) The radiotherapeutic management of optic nerve gliomas in children. Int J Radiat Oncol Biol Phys 6:45–50
Markesbery WR, McDonald JV (1973) Diencephalic syndrome long-term survival. Am J Dis Child 125:123–125
Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-Rose C, Kalifa C (1999) Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 45:393–396
Taphoorn MJ, Schiphorst AK, Snoek FJ, Lindeboom J, Wolbers JG, Karim AB, Huijgens PC, Heimans JJ (1994) Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36:48–54
Chong AL, Pole JD, Scheinemann K, Hukin J, Tabori U, Huang A, Bouffet E, Bartels U (2013) Optic pathway gliomas in adolescence–time to challenge treatment choices? Neuro Oncol 15:391–400
Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30:1358–1363
Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, Rutka J, Buncic JR, Bouffet E (2009) Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 53:1231–1237
Barlow SE (2007) Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120(Suppl 4):S164–S192
Green GJ, Weitzman SS, Pencharz PB (2008) Resting energy expenditure in children newly diagnosed with stage IV neuroblastoma. Pediatr Res 63:332–336
Energy and protein requirements (1985) Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser 724: 1–206
Schofield WN (1985) Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 39(Suppl 1):5–41
Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673–8677
von Hornstein S, Kortmann RD, Pietsch T, Emser A, Warmuth-Metz M, Soerensen N, Straeter R, Graf N, Thieme B, Gnekow AK (2011) Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: report from the HIT-LGG 1996 trial. Pediatr Blood Cancer 56:1046–1054
Sawamura Y, Kamoshima Y, Kato T, Tajima T, Tsubaki J (2009) Chemotherapy with cisplatin and vincristine for optic pathway/hypothalamic astrocytoma in young children. Jpn J Clin Oncol 39:277–283
Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 30:2641–2647
Cavicchiolo ME, Opocher E, Daverio M, Bendini M, Viscardi E, Bisogno G, Perilongo G, Da Dalt L (2013) Diencephalic syndrome as sign of tumor progression in a child with neurofibromatosis type 1 and optic pathway glioma: a case report. Childs Nerv Syst 29:1941–1945
Soucy EA, van Oppen D, Nejedly NL, Gao F, Gutmann DH, Hollander AS (2013) Height assessments in children with neurofibromatosis type 1. J Child Neurol 28:303–307
Clayton PE, Trueman JA (2000) Leptin and puberty. Arch Dis Child 83:1–4
Pons MA, Finlay JL, Walker RW, Puccetti D, Packer RJ, McElwain M (1992) Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. J Neurooncol 14:151–158
Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B (2009) Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 52:791–795
Acknowledgments
Supported by B.R.A.I.N. child, Canada (www.sickkids.ca/brainchild); Charity 10808 4419 RR 0001.
Conflict of interest
All authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Document written in accordance with the STROBE guidelines for observational studies.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kilday, JP., Bartels, U., Huang, A. et al. Favorable survival and metabolic outcome for children with diencephalic syndrome using a radiation-sparing approach. J Neurooncol 116, 195–204 (2014). https://doi.org/10.1007/s11060-013-1284-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-013-1284-2